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The job of transcribing a cell’s nuclear genes is shared by 
three enzymes called RNA polymerases. Each is essential for 
life, and each transcribes a different set of genetic templates. 
Focusing on RNA polymerase III (Pol III), which is implicated 
in both heart disease and cancer, an exciting new paper by 
Yee et al. supports the growing conviction that Pol III might 
prove useful as a novel therapeutic target. 
Pol III is highly specialized to produce only short 
untranslated RNAs, such as the transfer RNAs (tRNAs), 
which convert genetic information into protein sequences. 
Pol III activity is tightly linked to cell proliferation, probably 
because of tRNA’s role in protein synthesis. To maintain a 
constant size over successive generations, cells must double 
their mass—consisting of 80%–90% protein—before they 
divide. Ill-deﬁned checkpoints ensure that adequate mass has 
accumulated before the cell enters the S phase, when DNA is 
replicated. Thus, S phase entry and subsequent cell division 
depend on a cell’s ability to accumulate protein. S phase 
entry can be prevented in both yeast and cultured rodent 
cells by mutations in Pol III. Proliferation can be restrained 
when the p53 and retinoblastoma (RB) tumor suppressors 
inhibit Pol III transcription. Abnormal Pol III activity is a 
recurrent feature of human cancers [1].
The Pol III machinery has been very well characterized 
through genetic and biochemical approaches in yeast and 
has also been studied in mammalian cell lines. However, it 
has yet to be subjected to genetic analyses in vertebrates—a 
deﬁciency that Yee et al. have begun to redress using 
zebraﬁsh. They focused on a mutation called slim jim,
which was recovered in a large-scale mutagenesis screen for 
altered intestinal morphology. The mutation, which causes 
short deletions in Rpc2 (one of the 17 Pol III subunits), 
was predicted to affect the interface between Rpc2 and 
another subunit, Rpc11. To test this, the authors engineered 
an equivalent deletion in yeast Rpc2 and showed that the 
deletion compromises binding of Rpc11. Furthermore, 
they showed that the slim jim defect can be corrected 
by overexpressing Rpc11 in zebraﬁsh. These elegant 
experiments provide strong evidence for the predicted 
interaction between Rpc2 and Rpc11 in a complex metazoan.
Apart from the technical tour de force represented by 
this work, the consequences of the slim jim mutation are 
fascinating. As expected, the expression of Pol III products 
is compromised in the mutant, with tRNA levels reduced 
to about 40% of wild type. What is striking, however, is that 
the effects of this defect are only apparent in a subset of 
tissues, at least at the larval stages examined. These were 
highly proliferative tissues, including the liver and the 
digestive system. Effects were much less pronounced in tissues 
composed primarily of quiescent post-mitotic cells, such as 
those in heart and skeletal muscle. Severe defects were seen 
in the exocrine pancreas, which is populated with dividing 
cells, whereas normality reigned in the adjacent pancreatic 
islets, which stop expanding early in development. Cell cycle 
analysis suggested that S phase entry was reduced by nearly 
5-fold in the exocrine pancreas and 2-fold in the intestinal 
epithelium. This is strongly reminiscent of the cell-cycle arrest 
shown to result from certain temperature-sensitive Pol III 
mutations in budding yeast and cultured rodent cells.
Why do many organs appear normal when all cells 
depend on protein synthesis and hence tRNA and Pol III 
transcription for viability? Quiescent cells have much lower 
demands in this regard and so may cope with the diminished 
output of the slim jim mutant. Mitogenic stimuli trigger a 
substantial increase in the production of tRNA and protein 
that is required for passage into S phase; in all probability, the 
mutant Pol III is unable to meet the increase in demand that 
is essential for cell replication. 
What are the practical implications of Yee and colleagues’ 
evidence that diminished Pol III activity can interfere 
selectively with the most actively dividing groups of cells 
in an animal? It provides proof of principle that Pol III 
transcription offers a viable opportunity for attacking the 
most proliferative cells in a complex organism. A drug that 
speciﬁcally diminishes Pol III output, perhaps much less 
drastically than the slim jim mutation, might serve to arrest the 
cell cycle progression of cancer cells without causing excessive 
damage to healthy tissues with lower protein synthetic 
demands. As well as in hyperproliferative diseases, elevated 
Pol III activity is also a feature of cardiac hypertrophy, which 
depends on high rates of protein synthesis in the absence 
of cell division [2]. Slim jim might therefore be pointing 
the way toward novel routes for therapeutic intervention 
in cardiovascular disease as well as in cancer. Not bad for a 
skinny ﬁsh.
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